M Splanet Pharma ZAC DU Grand Launay Pharmaceutical Import Profile — France (DGFT 2022–2026)

Name: M Splanet Pharma ZAC DU Grand Launay Pharmaceutical Import Records from India — 3 Products, $322.9K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

M Splanet Pharma ZAC DU Grand Launay — Pharmaceutical Importer Profile (2026) | 3 Products, $322.9K Trade | TransData Nexus

Who Are the Verified Indian Suppliers to M Splanet Pharma ZAC DU Grand Launay?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Aurochem Pharmaceuticals India Private Limited	$916.0K	84	98.7%
Swiss Garnier Life Sciences	$11.8K	2	1.3%

M Splanet Pharma ZAC DU Grand Launay sources from 2 verified Indian suppliers across 66 distinct formulations. The sourcing is highly concentrated — Aurochem Pharmaceuticals India Private Limited accounts for 98.7% of total imports, indicating a strategic single-source relationship.

What Formulations Does M Splanet Pharma ZAC DU Grand Launay Import?

Formulation	Value	Ships
Pharmaceutical products-bonecare plus Each film coated tablet contains:glucosamine sulphate potassium chloride USP	$62.6K	2
Pharmaceutical products-oflozoleofloxacin & ornidazole tabletseach film coatedtablet contains:ofloxacin BP	$59.8K	2
Pharmaceutical products-feverlet forteaceclofenac paracetamol & chlorzoxazonetabletseach film coated tablet	$59.6K	4
Pharmaceutical products-welvit plusamino acids with vitamins & minerals capsules.Each capsule contains	$50.0K	1
Pharmaceutical products-defnil-pdiclofenac & paracetamol tabletseach uncoatedtablet contains : diclofenac sodium BP	$46.4K	3
Pharmaceutical products-aurother 80/480mgartemether & lumefantrine tabletseachuncoated tablet contains:artemether

What Products Does M Splanet Pharma ZAC DU Grand Launay Import?

Top Products by Import Value

1Glucosamine$140.3K 2Ornidazole$123.5K 3Chondroitin$59.2K

M Splanet Pharma ZAC DU Grand Launay Therapeutic Categories — 2 Specializations

M Splanet Pharma ZAC DU Grand Launay imports across 2 therapeutic categories, with Nutritional Supplements (61.8%), Advanced Antibiotics (38.2%), representing the largest segments. The portfolio is concentrated — top 5 products = 100% of total imports.

Nutritional Supplements

2 products · 61.8% · $199.5K

Import Portfolio — Top 3 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Glucosamine	Nutritional Supplements	$140.3K	7	1.1%	17
2	Ornidazole	Advanced Antibiotics	$123.5K	5	0.7%	17

Key Metrics

Total Import Value$322.9K

Products3

Shipments16

Categories2

CountryFrance

#1 Rankings0

Indian Suppliers2

Formulations66

Top Categories

Nutritional Supplements61.8%

Advanced Antibiotics38.2%

Last updated: March 28, 2026

M Splanet Pharma ZAC DU Grand Launay — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

M Splanet Pharma ZAC DU Grand Launay is a French pharmaceutical importer and distributor headquartered at 4 Avenue Victor Grignard, 76120 Le Grand Quevilly, France. The company specializes in sourcing finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, primarily from India. These products are then distributed within the French market, serving various healthcare providers and institutions. The company's strategic location in Le Grand Quevilly positions it advantageously within France's pharmaceutical distribution network, facilitating efficient logistics and supply chain operations.

2Distribution Network

M Splanet Pharma ZAC DU Grand Launay operates a centralized distribution model from its facility in Le Grand Quevilly. This location serves as the primary hub for receiving imported pharmaceutical products and dispatching them to various destinations across France. While specific details about additional warehouse locations or logistics capabilities are not publicly disclosed, the company's import activities suggest a well-established network capable of meeting the demands of the French pharmaceutical market.

Industry Role

Supplier Relationship Intelligence — M Splanet Pharma ZAC DU Grand Launay

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

M Splanet Pharma ZAC DU Grand Launay's sourcing strategy exhibits a high degree of concentration, with 98.7% of its imports originating from AUROCHEM PHARMACEUTICALS INDIA PRIVATE LIMITED. This single-source dependency indicates a strategic choice to maintain a streamlined supply chain, potentially benefiting from established relationships and favorable terms. However, such concentration also introduces risks related to supply chain disruptions, pricing fluctuations, and regulatory changes affecting the supplier. The company's limited engagement with other suppliers suggests a cautious approach to diversification, possibly due to considerations of quality control, cost efficiency, or contractual obligations.

2Supply Chain Resilience

The resilience of M Splanet Pharma ZAC DU Grand Launay's supply chain is closely tied to its reliance on AUROCHEM PHARMACEUTICALS INDIA PRIVATE LIMITED. The absence of backup suppliers and the limited diversity in imported formulations may pose challenges in the event of supply disruptions, such as production delays, shipping issues, or regulatory changes in India. Additionally, the company's focus on a narrow range of therapeutic categories—Nutritional Supplements and Advanced Antibiotics—limits its ability to adapt to shifts in market demand or therapeutic trends. To enhance supply chain resilience, the company might consider diversifying its supplier base and expanding its product portfolio to mitigate potential risks.

3Strategic Implications

M Splanet Pharma ZAC DU Grand Launay's concentrated sourcing strategy positions it to leverage strong relationships with its primary supplier, potentially securing favorable pricing and consistent product quality. However, this approach also exposes the company to risks associated with supply chain disruptions and market fluctuations. For Indian exporters, the company's focus on specific therapeutic categories presents an opportunity to introduce alternative products that align with M Splanet Pharma's existing portfolio, thereby reducing the risk of market entry. Diversifying the supplier base could also lead to more competitive pricing and improved supply chain stability.

TransData Nexus Research · Verified DGFT customs dataMar 2026

Importing Pharmaceuticals into France — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for France

1Regulatory Authority & Framework

In France, the primary regulatory authority overseeing pharmaceutical imports is the Agence nationale de sécurité du médicament et des produits de santé (ANSM). ANSM is responsible for ensuring the safety, efficacy, and quality of medicinal products available in the French market. Key legislation governing pharmaceutical imports includes the Public Health Code (Code de la santé publique), which outlines the requirements for marketing authorization, importation, and distribution of medicinal products. For Indian generics to be marketed in France, they must obtain a marketing authorization from ANSM, demonstrating compliance with French and European Union standards.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products in France stipulate that all imported medicines must have a valid marketing authorization issued by ANSM. Additionally, the manufacturing facilities of foreign suppliers must adhere to Good Manufacturing Practice (GMP) standards recognized by the European Union, WHO, or PIC/S. Indian exporters seeking to supply M Splanet Pharma ZAC DU Grand Launay must ensure that their manufacturing processes comply with these GMP standards and that their products are authorized for sale in France. Obtaining wholesale distribution authorization is also necessary for entities involved in the distribution of medicinal products within France.

3Quality & Labeling

Imported pharmaceutical products must undergo batch testing to confirm their quality, safety, and efficacy before being released into the French market. Stability studies are required to ensure that products maintain their intended quality throughout their shelf life. Labeling must be in French and include essential information such as the product name, active ingredients, dosage form, strength, batch number, expiration date, storage conditions, and instructions for use. Serialization mandates are in place to track and trace pharmaceutical products, enhancing supply chain security and preventing counterfeit products from entering the market.

4Recent Regulatory Changes

Between 2024 and 2026, France implemented several regulatory changes affecting pharmaceutical imports. These include stricter requirements for GMP compliance, enhanced pharmacovigilance measures, and updated labeling standards to improve patient safety and product traceability. Additionally, the French government introduced incentives for the importation of generic medicines to promote competition and reduce healthcare costs. Indian pharmaceutical exporters must stay informed about these regulatory developments to ensure continued market access and compliance.

TransData Nexus Research · France regulatory databasesMar 2026

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Analysis Methodology

1.Buyer Matching: M Splanet Pharma ZAC DU Grand Launay identified across shipments using consignee name normalization.
2.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
3.Market Share: Calculated per product as M Splanet Pharma ZAC DU Grand Launay's capped value divided by total Indian exports for that product.
4.Shipment Count: Based on 16 individual customs records matching M Splanet Pharma ZAC DU Grand Launay.
5.Supplier Verification: M Splanet Pharma ZAC DU Grand Launay sources from 2 verified Indian suppliers across 66 formulations, confirmed from customs records.

Government-Sourced Data

Official DGFT customs records

Transparent Methodology

Calculations fully disclosed above

3 Products Tracked

2 therapeutic categories

Expert-Reviewed

By pharmaceutical trade specialists

M Splanet Pharma ZAC DU Grand Launay

M Splanet Pharma ZAC DU Grand Launay — Import Portfolio & Supplier Network

Who Are the Verified Indian Suppliers to M Splanet Pharma ZAC DU Grand Launay?

What Formulations Does M Splanet Pharma ZAC DU Grand Launay Import?

What Products Does M Splanet Pharma ZAC DU Grand Launay Import?

Top Products by Import Value

M Splanet Pharma ZAC DU Grand Launay Therapeutic Categories — 2 Specializations

Import Portfolio — Top 3 by Import Value

Key Metrics

Top Categories

M Splanet Pharma ZAC DU Grand Launay — Corporate Profile & Information

1Company Overview

2Distribution Network

Industry Role

Indian Suppliers

Related Trade Data

Need Detailed Data?

Supplier Relationship Intelligence — M Splanet Pharma ZAC DU Grand Launay

1Sourcing Concentration Analysis

2Supply Chain Resilience

3Strategic Implications

Importing Pharmaceuticals into France — Regulatory Framework

1Regulatory Authority & Framework

2Import Licensing & GMP

3Quality & Labeling

4Recent Regulatory Changes

M Splanet Pharma ZAC DU Grand Launay — Procurement Pattern Analysis

1Product Strategy

2Sourcing Profile

3Market Positioning

Seller's Guide — How to Become a Supplier to M Splanet Pharma ZAC DU Grand Launay

1Opportunity Assessment

2Requirements & Qualifications

3How to Approach

Frequently Asked Questions — M Splanet Pharma ZAC DU Grand Launay

What products does M Splanet Pharma ZAC DU Grand Launay import from India?

Who supplies pharmaceuticals to M Splanet Pharma ZAC DU Grand Launay from India?

What is M Splanet Pharma ZAC DU Grand Launay's total pharmaceutical import value?

What therapeutic categories does M Splanet Pharma ZAC DU Grand Launay focus on?

Get Full M Splanet Pharma ZAC DU Grand Launay Import Intelligence

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

Analysis Methodology

Data Source & Methodology